However, in the case of cancer with the intact p53 pathway, the IDO1 expressed by the infiltrating immune cells may be able to activate GCN2K in cancer cells and inhibit tumor progression in a p53-dependent way. This evidence concerns the gene IDO1 and neoplasm.